Outcomes of screening Parkinson's patients for QTc prolongation

Parkinsonism and Related Disorders

Volumn 19, Issue 11, 2013, Pages 1000-1003

  Cunnington, Anne Louise ^a,b   Hood, Kay ^b   White, Lesley ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b STOBHILL HOSPITAL   (United Kingdom)

Author keywords

Medication; Parkinson's disease; QTc prolongation; Risk factors

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; DOMPERIDONE; FLUDROCORTISONE; HYDROXYCHLOROQUINE; MIRTAZAPINE; OLANZAPINE; QUETIAPINE; QUININE; SERTRALINE;

AGED; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRESCRIPTION; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; TORSADE DES POINTES;

MEDICATION; PARKINSON'S DISEASE; QTC PROLONGATION; RISK FACTORS;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LONG QT SYNDROME; MALE; MASS SCREENING; PARKINSON DISEASE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84886588961     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2013.07.001     Document Type: Article

References (21)

1. Straus S.M., Kors J.A., De Bruin M.L., Van der Hooft C.S., Hofman A., Heeringa J., et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. JAm Coll Cardiol 2006, 47:362-367.
2. Roden D.M. Drug therapy: drug-induced prolongation of the QT interval. NEngl J Med 2004, 350(10):1013-1022.
3. Yap Y.G., Camm A.J. Drug induced QT prolongation and torsades de pointes. Heart 2003, 89(11):1363-1372.
4. Medicines and Healthcare Products Regulatory Agency Citalopram and escitalopram: QT interval prolongation - new maximum daily dose restrictions (including in elderly patients), contraindications and warnings. Drug Saf Update Dec 2011, 5(5):A1.
5. Medicines and Healthcare products Regulatory Agency Domperidone: small risk of serious ventricular arrhythmia and sudden cardiac death. Drug Saf Update May 2012, 5(10):A2.
6. NHS Greater Glasgow and Clyde Medicines Information Service Drug induced QT prolongation. PostScriptExtra 2012, 21:1-3.
7. Nachimuthu S., Assar M.D., Schussler J.M. Drug-induced QT interval prolongation: mechanisms and clinical management. Ther Adv Drug Saf 2012, 3:241-253.
8. Pratt G., Medcalf P. Are patients with Parkinson's disease at risk of QTc prolongation and sudden death?. Age Ageing 2008, 37(Suppl.1):i41-i42.
9. Oka H., Mochio S., Sato H., Katayama K. Prolongation of QTc interval in patients with Parkinson's disease. Eur Neurol 1997, 37(3):186-189.
10. Deguchi K., Sasaki I., Tsukaguchi M., Kamoda M., Touge T., Takeuchi H., et al. Abnormalities of rate-corrected QT intervals in Parkinson's disease - a comparison with multiple system atrophy and progressive supranuclear palsy. JNeurol Sci 2002, 199:31-37.
11. Türk A.Ş., Köksal A., Altiokka Ö., Karademir F., Dirican A.C., Altunkaynak Y., et al. Assessment of autonomic dysfunction in Parkinson patients by electrocardiogram. JPsychiatry Neurol Sci 2012, 25:147-150.
12. Ishizaki F., Harada T., Yoshinaga H., Nakayama T., Yamamura Y., Nakamura S. Prolonged QTc intervals in Parkinson's disease - relation to sudden death and autonomic dysfunction. No To Shinkei 1996, 48:443-448. [Japanese].
13. Viskin S. The QT interval: too long, too short or just right. Heart Rhythm 2009, 6:711-715.
14. Talbot S. QT interval in right and left bundle-branch block. Br Heart J 1973, 35:288-291.
15. Malek N.M., Grosset K.A., Stewart D., Macphee G.J.A., Grosset D.G. Prescription of drugs with potential adverse effects on cardiac conduction in Parkinson's disease. Parkinsonism Relat Disord 2013, 19:586-589.
16. Seftchick M.W., Adler P.H., Heieh M., Wolfson A.B., Chan S.T., Webster B.W., et al. The prevalence and factors associated with QTc prolongation among emergency department patients. Ann Emerg Med 2009 Dec, 54(6):763-768.
17. Pasquier M., Pantet O., Hugli O., Pruvot E., Buclin T., Waeber G., et al. Prevalence and determinants of QT interval prolongation in medical inpatients. Intern Med J 2012, 42:933-940.
18. Golzari H., Dawson N.V., Speroff T., Thomas C. Prolonged QTc intervals on admission electrocardiograms: prevalence and correspondence with admission electrolyte abnormalities. Conn Med 2007, 71:389-397.
19. Montanez A., Ruskin J.N., Hebert P.R., Lamas G.A., Hennekens C.H. Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population. A review and qualitative overview of the prospective cohort studies. Arch Intern Med 2004, 164:943-948.
20. Malik M., Andreas J.-O., Hnatkova K., Hoeckendorff J., Cawello W., Middle M., et al. Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine. Clin Pharmacol Ther 2008, 84(5):595-603.
21. Hnatkova K., Smetana P., Toman O., Bauer A., Schmidt G., Malik M. Systematic comparisons of electrocardiographic morphology increase the precision of QT interval measurement. Pacing Clin Electrophysiol 2009, 32(1):119-130.